Literature DB >> 28970282

Hyperlipidemia-Induced MicroRNA-155-5p Improves β-Cell Function by Targeting Mafb.

Mengyu Zhu1, Yuanyuan Wei1,2, Claudia Geißler1, Kathrin Abschlag1, Judit Corbalán Campos1, Michael Hristov1, Julia Möllmann3, Michael Lehrke3, Ela Karshovska1,2, Andreas Schober4,2.   

Abstract

A high-fat diet increases bacterial lipopolysaccharide (LPS) in the circulation and thereby stimulates glucagon-like peptide 1 (GLP-1)-mediated insulin secretion by upregulating interleukin-6 (IL-6). Although microRNA-155-5p (miR-155-5p), which increases IL-6 expression, is upregulated by LPS and hyperlipidemia and patients with familial hypercholesterolemia less frequently develop diabetes, the role of miR-155-5p in the islet stress response to hyperlipidemia is unclear. In this study, we demonstrate that hyperlipidemia-associated endotoxemia upregulates miR-155-5p in murine pancreatic β-cells, which improved glucose metabolism and the adaptation of β-cells to obesity-induced insulin resistance. This effect of miR-155-5p is because of suppression of v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B, which promotes β-cell function through IL-6-induced GLP-1 production in α-cells. Moreover, reduced GLP-1 levels are associated with increased obesity progression, dyslipidemia, and atherosclerosis in hyperlipidemic Mir155 knockout mice. Hence, induction of miR-155-5p expression in β-cells by hyperlipidemia-associated endotoxemia improves the adaptation of β-cells to insulin resistance and represents a protective mechanism in the islet stress response.
© 2017 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28970282     DOI: 10.2337/db17-0313

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  21 in total

Review 1.  The Role of MicroRNAs in Hyperlipidemia: From Pathogenesis to Therapeutical Application.

Authors:  Yu Xiang; Li Mao; Mei-Ling Zuo; Gui-Lin Song; Li-Ming Tan; Zhong-Bao Yang
Journal:  Mediators Inflamm       Date:  2022-06-17       Impact factor: 4.529

Review 2.  Regulatory Non-coding RNAs in Atherosclerosis.

Authors:  Andreas Schober; Saffiyeh Saboor Maleki; Maliheh Nazari-Jahantigh
Journal:  Handb Exp Pharmacol       Date:  2022

3.  Substantially Altered Expression Profile of Diabetes/Cardiovascular/Cerebrovascular Disease Associated microRNAs in Children Descending from Pregnancy Complicated by Gestational Diabetes Mellitus-One of Several Possible Reasons for an Increased Cardiovascular Risk.

Authors:  Ilona Hromadnikova; Katerina Kotlabova; Lenka Dvorakova; Ladislav Krofta; Jan Sirc
Journal:  Cells       Date:  2020-06-26       Impact factor: 6.600

4.  rSjP40 suppresses hepatic stellate cell activation by promoting microRNA-155 expression and inhibiting STAT5 and FOXO3a expression.

Authors:  Dandan Zhu; Chunzhao Yang; Pei Shen; Liuting Chen; Jinling Chen; Xiaolei Sun; Lian Duan; Li Zhang; Jinhua Zhu; Yinong Duan
Journal:  J Cell Mol Med       Date:  2018-08-09       Impact factor: 5.310

Review 5.  The Role of MicroRNAs in Diabetes-Related Oxidative Stress.

Authors:  Mirza Muhammad Fahd Qadir; Dagmar Klein; Silvia Álvarez-Cubela; Juan Domínguez-Bendala; Ricardo Luis Pastori
Journal:  Int J Mol Sci       Date:  2019-10-31       Impact factor: 5.923

6.  α-Mangostin remodels visceral adipose tissue inflammation to ameliorate age-related metabolic disorders in mice.

Authors:  Dan Li; Qianyu Liu; Xiuqiang Lu; Zhengqiu Li; Chunming Wang; Chung-Hang Leung; Yitao Wang; Cheng Peng; Ligen Lin
Journal:  Aging (Albany NY)       Date:  2019-12-06       Impact factor: 5.682

7.  M2 macrophage-derived exosomal microRNA-155-5p promotes the immune escape of colon cancer by downregulating ZC3H12B.

Authors:  Yu-Shui Ma; Ting-Miao Wu; Chang-Chun Ling; Fei Yu; Jie Zhang; Ping-Sheng Cao; Li-Peng Gu; Hui-Ming Wang; Hong Xu; Liu Li; Zhi-Jun Wu; Gao-Ren Wang; Wen Li; Qin-Lu Lin; Ji-Bin Liu; Da Fu
Journal:  Mol Ther Oncolytics       Date:  2021-02-06       Impact factor: 7.200

Review 8.  Macrophage MicroRNAs as Therapeutic Targets for Atherosclerosis, Metabolic Syndrome, and Cancer.

Authors:  Yuanyuan Wei; Mengyu Zhu; Andreas Schober
Journal:  Int J Mol Sci       Date:  2018-06-13       Impact factor: 5.923

9.  Circulating plasma microRNA-126, microRNA-145, and microRNA-155 and their association with atherosclerotic plaque characteristics.

Authors:  Evija Knoka; Karlis Trusinskis; Mairita Mazule; Ieva Briede; William Crawford; Sanda Jegere; Indulis Kumsars; Inga Narbute; Dace Sondore; Aivars Lejnieks; Andrejs Erglis
Journal:  J Clin Transl Res       Date:  2020-01-13

Review 10.  The Role of microRNAs in Metabolic Syndrome-Related Oxidative Stress.

Authors:  Adam Włodarski; Justyna Strycharz; Adam Wróblewski; Jacek Kasznicki; Józef Drzewoski; Agnieszka Śliwińska
Journal:  Int J Mol Sci       Date:  2020-09-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.